Targeted Proteomics Driven Verification of Biomarker Candidates Associated with Breast Cancer Aggressiveness

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00209805%3A_____%2F18%3A00078033" target="_blank" >RIV/00209805:_____/18:00078033 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/00216224:14310/18:00101544

Výsledek na webu

<a href="https://www.ncbi.nlm.nih.gov/pubmed/29196895" target="_blank" >https://www.ncbi.nlm.nih.gov/pubmed/29196895</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1007/7651_2017_111" target="_blank" >10.1007/7651_2017_111</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Targeted Proteomics Driven Verification of Biomarker Candidates Associated with Breast Cancer Aggressiveness

Popis výsledku v původním jazyce

Breast cancer is the most common and molecularly well-characterized malignant cancer in women; however, its progression to metastatic cancer remains lethal for 78% of patients within 5 years of diagnosis. Identifying novel markers in high risk patients using quantitative methods is essential to overcome genetic, inter-tumor, and intra-tumor variability, and to translate novel findings into cancer diagnosis and treatment. Using untargeted proteomics, we recently identified 13 proteins associated with some key factors of breast cancer aggressiveness: estrogen receptors, tumor grade, and lymph node status. Here we verified these findings in a set of 96 tumors using targeted proteomics based on selected reaction monitoring with mTRAQ labeling (mTRAQ-SRM). This study highlights a panel of gene products that could contribute to breast cancer aggressiveness and metastasis, and can help develop more precise breast cancer treatments.

Název v anglickém jazyce

Targeted Proteomics Driven Verification of Biomarker Candidates Associated with Breast Cancer Aggressiveness

Popis výsledku anglicky

Breast cancer is the most common and molecularly well-characterized malignant cancer in women; however, its progression to metastatic cancer remains lethal for 78% of patients within 5 years of diagnosis. Identifying novel markers in high risk patients using quantitative methods is essential to overcome genetic, inter-tumor, and intra-tumor variability, and to translate novel findings into cancer diagnosis and treatment. Using untargeted proteomics, we recently identified 13 proteins associated with some key factors of breast cancer aggressiveness: estrogen receptors, tumor grade, and lymph node status. Here we verified these findings in a set of 96 tumors using targeted proteomics based on selected reaction monitoring with mTRAQ labeling (mTRAQ-SRM). This study highlights a panel of gene products that could contribute to breast cancer aggressiveness and metastasis, and can help develop more precise breast cancer treatments.

Druh

C - Kapitola v odborné knize

CEP obor

—

OECD FORD obor

30204 - Oncology

Projekt

<a href="/cs/project/GA17-05957S" target="_blank" >GA17-05957S: Evaluace nových potenciálních cílů a inhibitorů pro blokování vývoje metastáz u luminálních A nádorů prsu</a><br>

Návaznosti

P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)

Rok uplatnění

2018

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název knihy nebo sborníku

Tissue Proteomics: Methods in molecular biology

ISBN

978-1-4939-7852-6

Počet stran výsledku

8

Strana od-do

1-8

Počet stran knihy

320

Název nakladatele

Springer

Místo vydání

New York

Kód UT WoS kapitoly

—